Biorasi

Doff your caps to our CEO Chris O'Brien on teaching his first Harvard Business School class. The entire Biorasi #OneTeam is very proud!

Happy Thanksgiving from the Biorasi #OneTeam

10 Confessions Only Clinical Research Professionals Will Understand. Attention: Humor & The Funny Side of Our Roles Be honest, every clinical research role has its quirks, and sometimes they’re downright hilarious. Here are some totally relatable confessions: "As a Project Manager, I can confirm this timeline was created by an optimist on caffeine." "As a Medical Monitor, I can confirm this SAE report has more drama than a soap opera." "As a Clinical Trial Manager, I can confirm this meeting is yet another episode of “Who’s to Blame?” "As a CRA, I can confirm this site’s idea of “source documentation” is a napkin." "As a Clinical Project Associate, I can confirm this filing cabinet is where documents go to die." "As a Data Manager, I can confirm this query will outlive us all." "As a Regulatory Specialist, I can confirm this submission is so bad, it’s giving the FDA nightmares." "As a Pharmacovigilance Officer, I can confirm this adverse event has entered the “you won’t believe this” category." "As a Site Coordinator, I can confirm this CRA has confused “monitoring” with “micromanaging.”" "As a Monitoring Lead, I can confirm this site is held together by duct tape and sheer optimism." ?? Clinical research keeps us on our toes - and sometimes makes us laugh. Which of these resonates most with your role? Or better yet, share your own funny confession in the comments! #ClinicalResearch #ClinicalTrials #CRA #ProjectManagement #DataManagement #ResearchHumor #PharmaLife #ClinicalOps

We live in an age of scientific miracles. Among many other accomplishments this year: Scientists at the Karolinska Institutet reported they had developed nanorobots that can kill cancer in mice. Nanorobots! Researchers at MD Anderson Cancer Center identified a molecule that, in pre-clinical models, reduces age-related inflammation and enhances brain and muscle function, a potential longevity drug. And The Nobel Prize in #Chemistry went to #DavidBaker, Demis Hassabis, and John Jumper for breakthroughs in predicting protein structures. What once was often impossible, can now sometimes be done in seconds. This opens the door to new therapeutics and a deeper understanding of the causes of disease.? ? These breakthroughs and many others have enormous potential for human health. However, none of them really matter until they are validated through well-designed #clinicaltrials. ? Without the #clinicalresearch community, these advances could not help a single patient. The work we do is vital to the future of global health, and I feel lucky that I get to play a small part in it. ? It is #Thanksgiving week in the United States. This year, my talented colleagues at Biorasi – many of whom I saw live last week in Miami – as well as the broader clinical research community are on my gratitude list. Happy Thanksgiving!

At First Ascent Biomedical, we are proud to be thought leaders in the rapidly advancing field of Functional Precision Medicine (FPM), an approach that is redefining personalized cancer care. FPM combines cutting-edge science with actionable insights, enabling us to match patients with the most effective therapies, even when all other options have failed. The latest article in The ASCO interview with Diana Azzam, PhD underscores how Functional and Genomic Precision Medicine are converging to improve outcomes for cancer patients. It reinforces the vital role of innovative approaches like ours, which are delivering measurable results and transforming lives. At First Ascent, our Functional Precision Medicine platform has already demonstrated remarkable success in clinical studies, including an 83% improvement over the standard of care. This methodology goes beyond genomic testing by functionally testing hundreds of FDA-approved drugs against live patient biopsies to identify therapies that work in real time. Articles like this one validate the work we’re doing—not just in advancing cancer care but also in closing disparity gaps by bringing these solutions to underserved communities through initiatives like our Florida health disparity study and CLIA lab in Florida and Erie. The future of cancer treatment is here, and it’s personalized, patient-driven, and outcome-focused. We are honored to lead this charge and collaborate with partners across the medical and scientific community to ensure that every patient has access to the best possible care. Let’s continue the conversation: What excites you most about the potential of Functional Precision Medicine? https://lnkd.in/g-nEbFNT #PrecisionMedicine #FunctionalPrecisionMedicine #CancerCare #Innovation #FirstAscentBiomedical #ThoughtLeadership

Agree or disagree? "A well-managed trial is not only about avoiding problems; it’s about anticipating them and adapting quickly." In clinical research, challenges are inevitable. The real measure of success often lies in how prepared we are to face them and how agile we are in adapting to unexpected situations. I’d love to hear your thoughts - do you think proactive problem-solving is the key to trial success, or is there more to it? Let’s discuss! #ClinicalResearch #Leadership #ProblemSolving #ClinicalTrials __________________ Follow me on LinkedIn and subscribe to my newsletter on misterclinical.com Cheers, Vitali

The latest updates on #lymphoma research >> https://bit.ly/3VaRO2q

We had a great session yesterday with?Kristen K. Buck MD, our Senior Medical Advisor and a member of our Scientific Advisory Board. Kristen talked about?one of the toughest jobs in drug development:?being a?#ChiefMedicalOfficer?for a clinical stage biotech company. ? We work in a tough industry, and this is not an easy moment. Things move incredibly fast. People feel harried. Change is a constant. This makes?leading with #empathy?+ #curiosity a bigger challenge than ever. ? It also makes this more important. Walking in the shoes of clients and colleagues is critical to success. We asked Kristen to help us understand what keeps her, and her peers, up at night. ? In addition to being a key resource for?Biorasi?sponsors, Kristen serves as CMO and Head of R&D for?Lisata Therapeutics, Inc.?She shared lessons from the front lines, and she made two broader points I want to share: ? 1. Avoid surprises when you can, and bring thoughtful solutions when you can't. Change happens in?#clinicaltrials. The way we respond can mean the difference between success and failure.?Our responses can make meaningful impact on patients' lives. ? 2. Be brief. Be excellent. Be gone.?There's an old line that goes - "I'd have written you a shorter letter, but I didn't have the time." Take the time. Be concise. Value the time of your clients (and colleagues!). This was a great conversation. We'll do more of these with experts from key roles at sponsors. Recommendations appreciated! Thank you, Kristen!

When the CRA has seen the PI … only from a distance… Imagine this: You’re all set to meet the Principal Investigator and discuss the study, but instead, the Study Nurse walks in and says the PI is too busy to meet—maybe next visit. But uh-oh, you didn’t meet him during the last visit either, and the Report Reviewer has already raised concerns… Stressed, you go to grab a coffee, but the cup practically flies out of your hand as you catch a fleeting glimpse of the PI in the corridor! Well, TECHNICALLY, I HAVE SEEN HIM NOW—right? Fast forward to the monitoring report: “PI seen during visit. Confirmed. No further comments.” While this might sound humorous, it’s worth noting: seeing the PI for just one minute—or not seeing them at all after site activation—can be a strong indicator of why the site isn’t recruiting well or staying on track. Like, Follow and leave a comment! :) Cheers, Vitali #ClinicalResearch #CRA #MonitoringVisits #SiteVisits #HumorInResearch #ClinicalTrials __________________ Follow me on LinkedIn and subscribe to my newsletter on misterclinical.com

Patient perspectives and racial mistrust in #clinicalresearch >> https://bit.ly/410Zjg0